PPD has signed a contract with the U.S. government's Biomedical Advanced Research and Development Authority, agreeing to design and conduct clinical trials for products that protect against bioterrorism and other public health emergencies.
Waters Corp. inked a research partnership deal with an Irish research facility targeted toward developing a blood-based biomarker test that can predict whether a fetus is at high risk for premature birth.
Tesaro is making a move into the hot cancer immunotherapy field, paying $17 million upfront and offering milestones worth hundreds of millions more to work with AnaptysBio on a portfolio of antibodies that could be used in combination with its own pipeline drugs. And while one of the targets is PD-1, a popular subject in a field now dominated by Bristol-Myers Squibb and Merck, a pair of less familiar targets is also included in the package.
Fresh off scoring U.S. certification for its genomics lab, China's WuXi PharmaTech is amping up its lab testing services, buying into Illumina's $1,000 genome technology and teaming up with Pacific Biomarkers to broaden its assay menu.
Caisson Biotech, which signed on with Novo Nordisk in 2012 for the development of drugs using Caisson's delivery platform HEPtune, expanded the scope of the deal to cover specific indications, including its approach to insulin delivery.
Sanofi is joining forces with UCB to study new small-molecule approaches to treating inflammatory conditions like arthritis, looking for an easier form of administration to some of the blockbuster injected biologics that dominate the field. The pharma giant is ready to spend more than $138 million for a package of milestones and an upfront payment to UCB in exchange for the partnering arrangement with its NewMedicines research arm.
Eventual winner Johnson & Johnson wasn't Pharmacyclics' first choice to partner with on ibrutinib, CEO Robert Duggan told FierceBiotech in January, but, as The Wall Street Journal lays out, J&J and its expansive approach to dealmaking won out in the end.
Smith & Nephew has inked a co-marketing deal with OrthoSensor involving one of the company's orthopedic surgical tools. Neither side is discussing financial details.
A little biotech startup with an impressive lineup of biotech veterans among its backers has won over pharma giant Johnson & Johnson as an early partner on its plan to develop a new drug for Alzheimer's, currently one of the toughest targets in the drug business.
In the midst of rethinking its approach to R&D, AstraZeneca has dabbled in the virtual model of drug development, matching a small in-house staff with collaborators on contractors around the globe to make the process more efficient. Now, after some early success in neuroscience, the pharma giant is amping up its virtual efforts in oncology, signing a deal with a South Korean institution to hunt for new targets in the field.